Regencell Bioscience (RGC) Stock Statistics & Valuation Metrics

Regencell Bioscience has a market cap or net worth of $8.31B. The enterprise value is ―.

Regencell Bioscience has 494,488,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

Regencell Bioscience’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Regencell Bioscience is ―. Regencell Bioscience’s PEG ratio is 0.00.

In the last 12 months, Regencell Bioscience had revenue of 0.00 and earned -3.58M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -2.00M and capital expenditures -2.69K, giving a free cash flow of -2.00M billion.

Regencell Bioscience pays an annual dividend of $0.22, resulting in a dividend yield of ―

Regencell Bioscience upcoming earnings date is ―, ―.

Regencell Bioscience as a current ratio of ―, with Debt / Equity ratio of 0.00%

In the past 12 months, Regencell Bioscience has paid 0.00 in taxes.

Regencell Bioscience EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Regencell Bioscience has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $0.00 billion.

Gross margin is 0.00%, with operating margin of ―, and net profit margin of ―.

The average price target for Regencell Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―